Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Surgical Endoscopy
Published in: Surgical Endoscopy 8/2013

01-08-2013 | Letter to the Editor

From single protein to colorectal cancer genome landscape and network biology-based biomarkers

Author: Christof Hottenrott

Published in: Surgical Endoscopy | Issue 8/2013

Login to get access

Excerpt

To the Editor, …
Literature
1.
García-Alfonso P, Salazar R, García-Foncillas J, Musulén E, García-Carbonero R, Payá A, Pérez-Segura P, Ramón Y, Cajal S, Navarro S (2012) Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol 14(10):726–739PubMedCrossRef
2.
Roukos DH (2010) Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices 7(6):723–726PubMedCrossRef
3.
Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman V, Jaiswal BS, Guillory J, Ha C, Dijkgraaf GJ, Stinson J, Gnad F, Huntley MA, Degenhardt JD, Haverty PM, Bourgon R, Wang W, Koeppen H, Gentleman R, Starr TK, Zhang Z, Largaespada DA, Wu TD, de Sauvage FJ (2012) Recurrent R-spondin fusions in colon cancer. Nature 488(7413):660–664. doi:10.​1038/​nature11282 PubMedCrossRef
4.
Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407):330–337CrossRef
5.
Roukos DH (2010) Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med 4(4):583–586PubMedCrossRef
6.
Shantha Kumara HM, Kirchoff D, Herath SA, Jang JH, Yan X, Grieco M, Cekic V, Whelan RL (2012) Plasma levels of angiopoietin-like protein 4 (ANGPTL4) are significantly lower preoperatively in colorectal cancer patients than in cancer-free patients and are further decreased during the first month after minimally invasive colorectal ANGPTL4) resection. Surg Endosc 26(10):2751–2757CrossRef
7.
Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22:1553–1555PubMedCrossRef
8.
Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality-of-life improvement and challenges for improving long-term outcomes. Ann Surg 250:349–350PubMedCrossRef
9.
Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651PubMedCrossRef
10.
Liakakos T, Roukos DH (2008) Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? Surg Endosc 22:1402–1404PubMedCrossRef
11.
Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249:695–696PubMedCrossRef
12.
Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22:1405–1406PubMedCrossRef
13.
Nikiteas N, Roukos D, Kouraklis G (2011) Robotic versus laparoscopic surgery: perspectives for tailoring an optimal surgical option. Expert Rev Med Devices 8:295–298PubMedCrossRef
14.
Katsios GC, Baltogiannis G, Roukos DH (2010) Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Rev Anticancer Ther 10:473–476PubMedCrossRef
15.
Encke A (2011) KRAS mutation testing: Why is it now not recommended for colorectal cancer EGFR inhibitors treatment decision? Gastric Breast Cancer 10(4):220–222
16.
17.
Roukos DH (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8):1039–1043PubMedCrossRef
18.
Chin L, Andersen JN, Futreal PA (2011) Cancer genomics: from discovery science to personalized medicine. Nat Med 17:297–303PubMedCrossRef
19.
Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141
20.
Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM (2005) Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 5(4):737–745
21.
Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16(3):772–773
22.
Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250
23.
Roukos DH (2011) Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J 11(2):81–92
24.
Roukos DH (2011) Cancer genome explosion and systems biology: impact on surgical oncology? Ann Surg Oncol 18(1):12–15
25.
Roukos DH (2011) Chromatin: a key player in complex gene regulation and future cancer therapeutics. Epigenomics 3(4):395–399
26.
Roukos DH (2011) Networks medicine: from reductionism to evidence of complex dynamic biomolecular interactions. Pharmacogenomics 12(5):695–698
27.
Roukos DH (2011) Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices 8(2):123-126
28.
Roukos DH (2011) “Big” Science: genome regulatory networks and novel molecular tools to improve health. Expert Rev Mol Diagn 11(2):123-126
29.
Roukos DH (2011) Translating epigenetics into an anticancer drug pipeline for solid tumors. Expert Rev Med Devices 8(4):409–413
30.
Roukos DH (2010) Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol 28(17):e279–e280; author reply e282–e283
31.
Roukos DH (2012) Spatiotemporal individual genome code-lifestyle network: revolutionizing personal diagnostics. Expert Rev Mol Diagn 9(3):215–218
32.
Roukos DH (2012) Differential signalling transduction networks for clinical robustness. Expert Rev Proteomics 9(2):111–114
Metadata
Title
From single protein to colorectal cancer genome landscape and network biology-based biomarkers
Author
Christof Hottenrott
Publication date
01-08-2013
Publisher
Springer US
Published in
Surgical Endoscopy / Issue 8/2013
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-013-2852-4

Other articles of this Issue 8/2013

Surgical Endoscopy 8/2013 Go to the issue

Review

Defining technical errors in laparoscopic surgery: a systematic review

OriginalPaper

Ultrasound-guided percutaneous drainage of infected pancreatic necrosis

Review

Novel challenges of multi-society investigator-initiated studies: a paradigm shift for technique and technology evaluation

Letter to the Editor--Reply

Re: “Long-term comparison of laparoscopy-assisted distal gastrectomy and open distal gastrectomy in advanced gastric cancer” (Surg Endosc (2010) 24:1:63–67)

OriginalPaper

Is the transvaginal route appropriate for intra-abdominal NOTES procedures? Experience and follow-up of 222 cases

OriginalPaper

Cost analysis comparing ultrasonic fundus-first and conventional laparoscopic cholecystectomy using electrocautery